Skip to main content
TipRanks
Go Ultimate75% OFF

Clarity Pharmaceuticals Ltd. (CU6) Drug Pipeline

305 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
64Cu-Sar-BispsmaProstate Cancer, Prostate Cancer Patients With Detectable Psa Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant, Prostate Cancer Patients Treated By Radiotherapy, CryotherapyPhase IIIRecruiting64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate CancerApr 29, 2025―
64Cu-Sar-BispsmaProstate Cancer, Prostatic NeoplasmsPhase IIIRecruitingPositron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical ProstatectomySep 21, 2023―
64Cu-Sar-Bbn, 67Cu-Sar-BbnProstatic Neoplasms, Castration-Resistantphase1AndPhase2Terminated64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)Nov 21, 2022―
64Cu-Sar-BbnBiochemical Recurrence Of Malignant Neoplasm Of ProstatePhase IICompleted64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)Jun 02, 2022―
64Cu-Sar-Bispsma, 67Cu-Sar-BispsmaProstatic Neoplasms, Castration-Resistantphase1AndPhase2Recruiting64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)Apr 15, 2021―
64Cu-SartateNeuroendocrine TumorsPhase IICompletedA Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)Jun 11, 2020―
64Cu-Sartate, 67Cu-SartateNeuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastomaphase1AndPhase2Terminated67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory NeuroblastomaJul 14, 2019―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Clarity Pharmaceuticals Ltd. (AU:CU6) have in its pipeline
Clarity Pharmaceuticals Ltd. AU:CU6 is currently developing the following drugs: 64Cu-Sar-Bispsma, 64Cu-Sar-Bbn, 67Cu-Sar-Bbn, 64Cu-Sar-Bbn, 64Cu-Sar-Bispsma, 67Cu-Sar-Bispsma, 64Cu-Sartate, 64Cu-Sartate, 67Cu-Sartate. These drug candidates are in various stages of clinical development as the company works toward FDA approval.